Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00450567
Status:
COMPLETED
Last Update Posted:
2020-08-03
First Post:
2007-03-20
Brief Title:
Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Study Overview
Official Title:
Monitoring Targeted Lung Cancer Treatments With FDG-PETCT
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Measuring changes in glucose metabolism in patients with cancer may help doctors predict how patients respond to treatment
PURPOSE This clinical trial is studying glucose metabolism in patients with non-small cell lung cancer treated with targeted therapy and chemotherapy
PURPOSE This clinical trial is studying glucose metabolism in patients with non-small cell lung cancer treated with targeted therapy and chemotherapy
Detailed Description:
OBJECTIVES
Determine the prognostic significance of changes in glucose metabolism measured by fludeoxyglucose F 18 positron emission tomography FDG-PETCT scan in patients with non-small cell lung cancer treated with targeted drugs comprising gefitinib erlotinib hydrochloride or other ErbB inhibitors cyclooxygenase-2 inhibitors or estrogen receptor blockers in combination with conventional chemotherapy
OUTLINE This is a prospective study
Patients undergo fludeoxyglucose F 18 positron emission tomography FDG-PET scan and CT scan at baseline and at 2 weeks and 12 weeks after receiving targeted anticancer treatment Metabolic changes detected by FDG-PET and size changes identified by CT scan are related to patient outcome and tumor response to treatment
PROJECTED ACCRUAL A total of 120 patients will be accrued for this study
Determine the prognostic significance of changes in glucose metabolism measured by fludeoxyglucose F 18 positron emission tomography FDG-PETCT scan in patients with non-small cell lung cancer treated with targeted drugs comprising gefitinib erlotinib hydrochloride or other ErbB inhibitors cyclooxygenase-2 inhibitors or estrogen receptor blockers in combination with conventional chemotherapy
OUTLINE This is a prospective study
Patients undergo fludeoxyglucose F 18 positron emission tomography FDG-PET scan and CT scan at baseline and at 2 weeks and 12 weeks after receiving targeted anticancer treatment Metabolic changes detected by FDG-PET and size changes identified by CT scan are related to patient outcome and tumor response to treatment
PROJECTED ACCRUAL A total of 120 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UCLA-0410068-01 | US NIH GrantContract | None | httpsreporternihgovquickSearchP50CA086306 |
| P50CA086306 | NIH | None | None |